| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2014: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we explored genes whose knockdown promotes esophageal cancer cells increased sensitivity or resistance to anticancer drugs using genome-wide RNA interference screening.
First, we performed positive-selection screening. We infected esophageal cancer cells (KYSE170) with shRNA pool and then treated cells with cisplatin. We obtained a dozen sublines from KYSE170 that were resistant to cisplatin. We identified genes whose inhibition rendered esophageal cells resistant to cisplatin.
Next, we performed negative-selection screening. We divided shRNA-infected KYSE170 cells into two groups and administered cisplatin to one group. Then we compared the abundance of each shRNA. We found that the inhibition of genes involved in nucleotide excision repair and histone modification increased cisplatin sensitivity of esophageal cancer cells.
|
